Esperion Therapeutics

Yahoo Finance • yesterday

Familial Hypercholesterolemia Market Intelligence Report 2025-2035 Featuring Regeneron, Amgen, Esperion, Aegerion, Novartis and Other Key Players - Precision Medicine Fuels Personalized Treatment Approaches

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Familial Hypercholesterolemia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.... Full story

Yahoo Finance • 3 days ago

Esperion a new overweight at Piper Sandler on CV franchise

[Wall Street sign with American flag in the background, symbolizing the financial heart of New York.] Piper Sandler has initiated coverage of Esperion Therapeutics (ESPR [https://seekingalpha.com/symbol/ESPR]) at overweight stating that t... Full story

Yahoo Finance • 7 days ago

Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

– Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ANN ARBOR, Mich., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Esperion (... Full story

Yahoo Finance • 10 days ago

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and... Full story

Yahoo Finance • 22 days ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 4, 2025, the Company granted 23 new employees 77,650 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incen... Full story

Yahoo Finance • 22 days ago

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update

– Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million – – Q3 2025 U.S. Net Product Revenue Grew 31% Y/Y to $40.7 Million – – Reached Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLET... Full story

Yahoo Finance • 23 days ago

Esperion Therapeutics Q3 2025 Earnings Preview

* Esperion Therapeutics (ESPR [https://seekingalpha.com/symbol/ESPR]) is scheduled to announce Q3 earnings results on Thursday, November 6th, before market open. * The consensus EPS Estimate is -$0.07 [https://seekingalpha.com/symbol/E... Full story

Yahoo Finance • last month

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, LA, N... Full story

Yahoo Finance • 2 months ago

Biggest stock movers Wednesday: JOBY, IREN, and more

[Strategy stock chart financial graph analysis market exchange on growth business technology background with money diagram trade investment or digital progress candlestick finance data global success.] Lemon_tm Stock futures edged higher... Full story

Yahoo Finance • 2 months ago

Esperion Announces Pricing of Public Offering of Common Stock

ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-st... Full story

Yahoo Finance • 2 months ago

Esperion launches proposed public offering of common stock

* Esperion Therapeutics (NASDAQ:ESPR [https://seekingalpha.com/symbol/ESPR]) has commenced an underwritten public offering of shares of its common stock. Esperion also intends to grant the underwriters a 30-day option to purchase up to a... Full story

Yahoo Finance • 2 months ago

Esperion Announces Proposed Public Offering of Common Stock

ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-st... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Gain Late Afternoon

Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index and the Health PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Esperion settles patent dispute with Dr. Reddy’s over cholesterol drugs

[Artificial Intelligence helping improve human life and health digital concept] Vertigo3d/E+ via Getty Images * Esperion Therapeutics (NASDAQ:ESPR [https://seekingalpha.com/symbol/ESPR]) announced it has reached a settlement with Dr. Re... Full story

Yahoo Finance • 2 months ago

Oritain expands traceability offer to leather

Oritain’s proprietary methodology, already trusted across apparel, food, and agriculture, can now verify the geographic origin of leather from key producing countries across Europe, Africa and South America. Oritain says this capability i... Full story

Yahoo Finance • 2 months ago

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

ANN ARBOR, Mich., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner for the development and commercialization of NEXLETOL® (bempedoic acid) tab... Full story

Yahoo Finance • 3 months ago

Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

– Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence – – Guideline Recognition of ‘Strike Early and Strike Strong’ Approach with Early Combination Lipid-Lowering Therap... Full story

Yahoo Finance • 4 months ago

Esperion rises after revenue beat, Q1 profitability expectation

[display stock market charts] loveguli/E+ via Getty Images Esperion Therapeutics (NASDAQ:ESPR [https://seekingalpha.com/symbol/ESPR]) shares rose on Tuesday after the company reported second quarter revenue above estimates, and now expect... Full story

Yahoo Finance • 4 months ago

Esperion Therapeutics Inc (NASDAQ:ESPR) Beats Q2 2025 Revenue Forecasts and Reduces Losses Amid Strong Prescription Growth

ESPERION THERAPEUTICS INC (NASDAQ:ESPR [https://www.chartmill.com/stock/quote/ESPR/profile]) SURPASSES REVENUE ESTIMATES, NARROWS LOSSES IN Q2 2025 Esperion Therapeutics Inc (NASDAQ:ESPR [https://www.chartmill.com/stock/quote/ESPR/profile... Full story

Yahoo Finance • 4 months ago

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

– Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached Settlement Agreements with T... Full story